WithdrawnPhase 1

The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients

Stopped: Difficulties in working across borders due to sanctions

Iran0Started 2026-01-29

Plain-language summary

The projects investigate if treatment with isocapnic hyperventilation can eliminate methanol from the body in a similar manner to dialysis. This is achieved by administering the antidote (fomepizole) and let the patient breathe on a isocapnic hyperventilation device while samples of blood, urine and maybe the breath are collected to measure the contents of methanol and its metabolites.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients, men \& women diagnosed with methanol poisoning * Serum-methanol ≥ 50 mg/dL (16 mM) * pH ≥ 7.0, and correctable by bicarbonate infusion * no (newly developed) visual disturbances Exclusion Criteria: * Acidosis requiring haemodialysis (pH \<7.0), or acidosis that is not responding in spite of aggressive buffer (bicarbonate) treatment within maximum 1-2 hours. * Comatose patients * Newly developed visual disturbances * ADH not fully blocked with antidotes, and not responding to additional dosing of fomepizole. Will be identified by a continuous or increasing anion gap (AG) or Base Excess (BE) on the blood gas machine.

What they're measuring

Characterization of methanol elimination kinetics, when iHV is utilized

Timeframe: 0-40 hours

Trial details

NCT IDNCT06173817

SponsorOslo University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-01-29

View on ClinicalTrials.gov More Methanol Poisoning trials